34680-81-4

Basic information

• Product Name: 2-BROMO-N-METHYLACETAMIDE
• Synonyms: 2-BROMO-N-METHYLACETAMIDE;CHEMBRDG-BB 4023689;acetamide, 2-bromo-N-methyl-;2-bromo-N-methylacetamide(SALTDATA: FREE);2-bromo-N-methyl-ethanamide
• CAS NO: 34680-81-4
• Molecular Formula: C₃H₆BrNO
• Molecular Weight: 151.99
• Mol File: 34680-81-4.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 273.6 °C at 760 mmHg
• Flash Point: 119.3 °C
• Appearance: /
• Density: 1.564 g/cm³
• Vapor Pressure: 0.00568mmHg at 25°C
• Refractive Index: 1.473
• PKA: 14.01±0.46(Predicted)
• CAS DataBase Reference: 2-BROMO-N-METHYLACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-N-METHYLACETAMIDE(34680-81-4)
• EPA Substance Registry System: 2-BROMO-N-METHYLACETAMIDE(34680-81-4)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 34680-81-4(Hazardous Substances Data)

Usage

General Description

2-Bromo-N-methylacetamide is an organic chemical compound with the molecular formula C3H6BrNO. It is a white to off-white crystalline powder that is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. This chemical is also used as an intermediate in the manufacturing of other organic compounds, such as dyes and polymers. It is important to handle this chemical with care and use appropriate safety measures, as it can be harmful if ingested, inhaled, or in contact with skin. Additionally, it may cause irritation to the skin, eyes, and respiratory system.

InChI:InChI=1/C3H6BrNO/c1-5-3(6)2-4/h2H2,1H3,(H,5,6)

Upstream product

• 79-08-3 bromoacetic acid 
• 74-89-5 methylamine 
• 598-21-0 2-Bromoacetyl bromide 
• 22118-09-8 2-bromoacetyl chloride 
• 593-51-1 methylamine hydrochloride 

Downstream Products

• 57837-07-7 2-(2,6-Diethyl-phenylamino)-N-methyl-acetamide 
• 313681-29-7 (3R,3AS,6AR)-Hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-3-[(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino]-2-hydroxy-1-(4-[2-(methylamino)-2-oxoethoxy]benzyl}propylcarbamate 
• 333963-31-8 2-{[6-Amino-3,5-dicyano-4-(4-hydroxyphenyl)-2-pyridinyl]sulfanyl}-N-methyl-acetamide 
• 265983-58-2 N,N-dimethyl(2-benzyloxy-3,5-dimethyl)phenoxyacetamide 
• 1277182-11-2 1-benzyloxycarbonyl-1,4,7,10-tetraazacyclododecane-4,7,10-tri(methylcarbonylamide) 
• 1277182-09-8 2-p-nitrobenzyl-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methylcarbonylamide) 
• 1207634-61-4 2-[6-(3-fluoro-4-hydroxybenzyl)-1-oxo-1,2,4,7-tetrahydro-3H-indolo[2,3-c][1,7]naphthyridin-3-yl]-N-methylacetamide 
• 1207634-51-2 2-[6-(3-fluoro-4-methoxybenzyl)-1-oxo-1,2,4,7-tetrahydro-3H-indolo[2,3-c][1,7]naphthyridin-3-yl]-N-methylacetamide 
• 1021245-67-9 2-[(4-methoxyphenyl)amino]-N-methylacetamide 
• 164210-32-6 (S)-(+)-2-(4-hydroxyphenyl)propionic acid N-methylcarbamoylmethyl ester 
• 59721-14-1 N-methylcarbamoylmethyl-p-hydroxybenzoate 
• 55882-98-9 2,6-dimethylanilinoacetic acid methyl amide 
• 52121-03-6 N-ethylcarbamoyl-N-(5-nitro-thiazol-2-yl)-glycine methylamide 
• 5756-19-4 S,S'-Dimethyl-S''-trithiophosphat 

Relevant articles and documents

Structure–Activity and Structure–Toxicity Relationships of Peptoid-Based Histone Deacetylase Inhibitors with Dual-Stage Antiplasmodial Activity

Novel malaria intervention strategies are of great importance, given the development of drug resistance in malaria-endemic countries. In this regard, histone deacetylases (HDACs) have emerged as new and promising malaria drug targets. In this work, we present the design, synthesis, and biological evaluation of 20 novel HDAC inhibitors with antiplasmodial activity. Based on a previously discovered peptoid-based hit compound, we modified all regions of the peptoid scaffold by using a one-pot multicomponent pathway and submonomer routes to gain a deeper understanding of the structure–activity and structure–toxicity relationships. Most compounds displayed potent activity against asexual blood-stage P. falciparum parasites, with IC50 values in the range of 0.0052–0.25 μm and promising selectivity over mammalian cells (SIPf3D7/HepG2: 170–1483). In addition, several compounds showed encouraging sub-micromolar activity against P. berghei exo-erythrocytic forms (PbEEF). Our study led to the discovery of the hit compound N-(2-(benzylamino)-2-oxoethyl)-N-(4-(hydroxycarbamoyl)benzyl)-4-isopropylbenzamide (2 h) as a potent and parasite-specific dual-stage antiplasmodial HDAC inhibitor (IC50 Pf3D7=0.0052 μm, IC50 PbEEF=0.016 μm).

Synthesis and preliminary evaluation of novel 11C-labeled GluN2B-selective NMDA receptor negative allosteric modulators

N-methyl-D-aspartate receptors (NMDARs) play critical roles in the physiological function of the mammalian central nervous system (CNS), including learning, memory, and synaptic plasticity, through modulating excitatory neurotransmission. Attributed to et

GluN2B subunit targeting central nervous system positron tracer and preparation thereof

The existing GluN2B selective positron tracer has relatively high affinity and selectivity, but does not show ideal tracer properties in an in vivo experiment, has the problems of overquick metabolism, lower brain uptake, undifferentiated distribution in the whole brain, overquick degradation of C-11 labeled probe and off-target phenomenon caused by influence of other target spots in the brain, which limit the further translational research. The invention designs a novel GluN2B subunit targeting central nervous system positron tracer, reduces the metabolism rate of the tracer and prolongs theservice time by utilizing the characteristics that a methylamino structure is stable and not easy to metabolize. Meanwhile, the tracer of the invention is easy to be detected and traced through experiments, and has a better electron tracing effect. In addition, a preparation method provided by the invention is mild in conditions, and can quickly obtain a high-purity C11-labeled tracer injection,so as to effectively solve the problem of overquick degradation of the C-11 labeled probe.